Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
41.47
-1.49 (-3.47%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Monopar Therapeutics stock have an average target of 59.5, with a low estimate of 40 and a high estimate of 76. The average target predicts an increase of 43.48% from the current stock price of 41.47.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | -3.54% | Apr 1, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $76 | Buy | Initiates | $76 | +83.27% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $40 | Strong Buy | Maintains | $22 → $40 | -3.54% | Jan 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $72 | Buy | Initiates | $72 | +73.62% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 77.96M
Revenue Next Year
n/a
EPS This Year
-2.65
from -4.11
EPS Next Year
-1.98
from -2.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 5.7M | 46.7M | ||
| Avg | n/a | 3.1M | 23.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,390.4% | ||
| Avg | - | - | 663.3% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.98 | -1.76 | 0.76 | ||
| Avg | -2.65 | -1.98 | -0.31 | ||
| Low | -3.47 | -2.16 | -1.49 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.